EFCCA Clinical Trial News
EFCCA is pleased to bring you some scientific and medical articles related to IBD for your information. EFCCA cannot accept any liability for the accuracy of the information, or for the use of it. Whilst discussion of potential therapies has academic value, EFCCA would like to remind all readers that no claims are made on the effectiveness or safety of any treatment, and that readers should always consult their healthcare professional if they have any concerns or questions, and before taking any action based on the information.
As many of us unfortunately know, fatigue is said to be one of the ‘big three’ symptoms of IBD (pain, fatigue, and urgently needing the toilet).
As several important articles note that anaemia may be especially significant in people with IBD, EFCCA, supported by Vifor Pharmaceuticals and A+A Research, are currently carrying out a survey to understand:
- The effects of anaemia in IBD from the patient’s perspective
- The effect of fatigue on a variety of activities in daily life
- How healthcare professionals approach and communicate anaemia in IBD
With the knowledge from this focused survey, we hope to be able to gain more detail about the precise impact that this symptom has, which could help us better understand the problem, raise awareness, and capture the attention of those in a position to help us with the aspects of daily life that are affected.
Take part in this exciting survey at: http://www.efcca-solutions.net/anaemia/
The new AEGIS-1, and The new AEGIS-1, and AEGIS-2 studies are aiming to find out whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in non-active ulcerative colitis (UC), and non-active Crohn’s disease (CD).